400-9696-311 转1
400-9696-311 转3
400-9696-311 转4
400-9696-311 转5
400客服电话
购买数据产品
400-9696-311 转1
定制咨询业务
400-9696-311 转2
数据与AI定制业务
400-9696-311 转3
商务合作及其他问题
400-9696-311 转4
投诉及建议
400-9696-311 转5
ChiCTR-IPR-17013088
尚未开始
/
/
/
2017-10-23
/
/
帕金森氏病
Clinical study of localized Tui Na combination with points press in reducing the symptoms of knee stiffness in Parkinson's disease: A Randomized Pilot Clinical Trial
Clinical study of localized Tui Na combination with points press in reducing the symptoms of knee stiffness in Parkinson 's disease: A Randomized Pilot Clinical Trial
i. To evaluate the efficacy of localized Tui Na combining with points press (Abbreviated as LTNCPP) in reducing the motor symptoms of PD especially focusing on releasing lower limbs movement barriers and muscles dysfunction; ii. To evaluate the safety of LTNCPP in subjects with idiopathic PD in a randomized clinical trial.
随机平行对照
探索性研究/预试验
A random number sequence will be generated with computer by Co-investigator (Co II), kept in a sealed envelope, and sent to Viven Law in Hong Kong.
/
Student Honors Project Funding
/
20
/
2017-04-01
2018-01-31
/
Patients will be included if they have all the following: 1. Meet UKPDBB criteria; 2. Age of 18 to 80 years (inclusive); 3. have the symptoms of LLMB; 4. Stable treatment with levodopa, alone or in combination with other antiparkinsonian drugs or any other treatment over the last 2 months; 5. does not have any bone fractures or operation history over last half year.;
请登录查看Patients will be excluded if they have one or more of the following: 1. Atypical or secondary Parkinsonism; 2. with any other severe diseases (i.e. cancer and acute present asthma); 3. operation history or trauma history over last half year; 4. Pregnancy or are breast feeding.;
请登录查看香港浸會大學中醫藥學院
/
德琪医药2026-07-20
动脉网-最新2026-07-20
药精通Bio2026-07-20
求实药社2026-07-20
求实药社2026-07-20
康方生物Akeso2026-07-20
干细胞与外泌体2026-07-20
加科思2026-07-20
良医汇肿瘤资讯2026-07-19
GLP1减重宝典2026-07-19